Development of Clinical Imaging and Drugs and Enhancers
Until 2009, the Development of Clinical Imaging Drugs & Enhancers (DCIDE) program sought applications to supply or enable missing steps so that promising imaging agents could be translated to the clinical research environment despite the absence of development capacity, clinical connections, or industry interest. The DCIDE program focused on promising diagnostic agents that were not otherwise likely to undergo adequate preclinical testing to warrant an IND application. As of August 2009, DCIDE closed to new applications. Now, projects that would have fit into DCIDE and applications focusing on imaging drug development resources should be requested through the NCI Experimental Therapeutics Program (NExT) program, which has its own application and review process. There are four review dates per year for NExT.
Paula M. Jacobs, Ph.D., is Associate Director, Cancer Imaging Program in the Division of Cancer Treatment and Diagnosis at the National Cancer Institute. She came to work at the NCI after 30 years in the pharmaceutical and medical device industries where she was a key developer of ultrasmall superparamagnetic iron oxide drugs as magnetic resonance imaging agents and iron replacement therapeutics. More…